# Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial

> **NCT01657461** · NA · COMPLETED · sponsor: **Medtronic Neurovascular Clinical Affairs** · enrollment: 196 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
- **DEVICE:** Solitaire revascularization device

## Key facts

- **NCT ID:** NCT01657461
- **Lead sponsor:** Medtronic Neurovascular Clinical Affairs
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2017-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01657461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01657461, "Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01657461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*